The 3.2 angstrom structure of a bioengineered variant of blood coagulation factor VIII indicates two conformations of the C2 domain.Smith, I.W., d'Aquino, A.E., Coyle, C.W., Fedanov, A., Parker, E.T., Denning, G., Spencer, H.T., Lollar, P., Doering, C.B., Spiegel Jr., P.C.
(2020) J Thromb Haemost 18: 57-69
- PubMed: 31454152
- DOI: https://doi.org/10.1111/jth.14621
- Primary Citation of Related Structures:
- PubMed Abstract:
Coagulation factor VIII represents one of the oldest protein-based therapeutics, serving as an effective hemophilia A treatment for half a century. Optimal treatment consists of repeated intravenous infusions of blood coagulation factor VIII (FVIII) per week for life. Despite overall treatment success, significant limitations remain, including treatment invasiveness, duration, immunogenicity, and cost. These issues have inspired research into the development of bioengineered FVIII products and gene therapies.
Department of Pediatrics, Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, Georgia.